Transdermal Fentanyl as a Form of Rebound Pain Reduction in Fast Track Programme in Primary Knee Arthroplasty.
Launched by OSCAR DIAZ-CAMBRONERO · May 21, 2024
Trial Information
Current as of February 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Total knee arthroplasty (TKA from now on) is a frequent surgery in routine clinical practice in constant evolution and improvement, with the objective being the earliest possible functional recovery of these patients, the role of the anaesthesiologist being fundamental in this sense throughout the perioperative period since, as we know, it is a surgery that improves the mobility and quality of life of the patient, but causes intense postoperative pain during the first 24 to 72 hours, it is a surgery that improves the patient's mobility and quality of life, but causes intense postoperative p...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients undergoing primary knee arthroplasty ASA I-III between 18 and 80 years of age who have received a transdermal fentanyl patch or morphine PCA as part of their postoperative analgesic strategy
- Exclusion Criteria:
- • Prior opioid treatment.
- • History of previous opioid adverse effects.
- • History of PONV.
- • History of medical history that conditions baseline alteration of the data to be collected.
- • Contraindication to neuroaxial techniques.
- • Difficulty in understanding the scales used.
- • Patient's refusal.
About Oscar Diaz Cambronero
Oscar Diaz-Cambronero is a distinguished clinical trial sponsor dedicated to advancing medical research through innovative trial designs and rigorous protocols. With a strong emphasis on patient safety and ethical standards, his work focuses on developing effective therapies across various therapeutic areas. Leveraging extensive experience in clinical operations and regulatory compliance, Diaz-Cambronero collaborates with healthcare professionals and research institutions to ensure the successful execution of clinical trials, ultimately aiming to enhance patient outcomes and contribute to the body of scientific knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0